What is malaria resistance?
The term "resistance to malaria" can be used to indicate two different concepts related to malaria. The first is natural resistance to parasites that cause malaria observed in some human populations. The second is the development of drug resistance in parasites Plasmodium , causal agents for malaria, making the treatment of malaria more difficult, because normally effective drugs become unnecessary. Both concepts are very interesting for medical researchers and scientists, as well as for genetics. When the human populations began to engage in agriculture, the landscape change to create the conditions hospitable for anopheles mosquito, which bear malaria, genetic features that brought me some resistance to malaria infection. The selection of these qualities began to occur because people with features survive malaria, while people without them.
Using DNA analysis, scientists were able to determine the era when in the human populationResistance to malaria began to discover. It can also be monitored to specific areas, showing that the resistance has developed specifically in the "belt malaria" rather than spontaneously. However, malaria resistance came at the price. The evolutionary features that provide resistance could also be deadly, as can be seen in conditions such as thalassemia anemia and anemia of sickle cells. While these features limit the activities of plasmodium in the body and create resistance to malaria, if people inherit the wrong combination of properties, they can experience blood disorders.
In the Plasmodium populations, resistance to antimalarial drugs is a global problem. Like other microorganisms, these parasites are very adaptable, so you can make changes in conditions and use new ecological niches. When organisms are exposed to antimalarial drugs, some inevitably have a certain natural resistance that allows them to survive, and over time resistant organisms behave with other rby essential organisms and create descendants that have greater resistance.
Resistance to antimalarial drugs is a problem for pharmaceutical companies and auxiliary organizations working in regions where malaria is widespread. It is necessary to develop new drug classes to treat malaria to remain before developing medicines that can target organisms that tolerate conventional antimalars classes. The problem is that the research is extremely expensive and some pharmaceutical companies are reluctant to participate in it because payouts for antimalars tend to be lower than medicines that can be sold in the developed world.